By 2011, sales had surged to more than half a billion dollars annually. That year, Taiwanese cell-phone maker HTC put up $300 million to buy a 51% stake in Beats. The partnership, which seemed like an ideal way to match the headphones business with the fast-growing one for mobile devices, allowed Iovine and Dre to break away from Monster completely by the end of 2012 and set up their own manufacturing. But despite aggressive co-branding, the HTC partnership didn't yield any mega-hits. Last year, the duo bought back outstanding shares from HTC and raised a $500 million investment from the Carlyle Group, a private-equity giant. Dre and Iovine still own a controlling stake in the company.
6.Whom may you contact for HTC common shareholder services? If you have any questions concerning your common shares, please call The Transfer Agency Department of Chinatrust Commercial Bank in Taiwan at 886-2-2181-1911.
HTC Buy back their own shares
Download: https://urlgoal.com/2vDIUS
9.What do you need to do in order to participate in HTC's dividend payments? A shareholder must own HTC shares through the day before the ex-dividend date to be entitled to the proposed dividend payment.
HTC is selling back the remainder of its stake in Beats Electronics, shedding its financial ties to the headphones vendor in a partnership that did little to help turn the smartphone maker's fortunes around.
Last year in July, HTC scaled back its financial ties to Beats and sold off half of its majority stake in the company for $150 million. At the time, HTC said the move would give Beats more flexibility to expand globally. But analysts also said the Beats partnership had failed to give HTC a significant edge over its rivals.
We each had to submit videos online that best showcased our individual personality, dance technique, fitness, and ability to learn and perform a routine in an efficient amount of time. While this was uniquely challenging, it was also highly rewarding. In fact, I was fortunate enough to have a best friend on the team, who was also trying out again, and who offered her dancing space to film my audition videos. In addition to that, I received some of the sweetest, most encouraging messages from my fellow teammates throughout the entire process. To me, this demonstrated just how close-knit our sisterhood is, and that we can always lean on each other for support. This kind of comradery is what makes being an HTC so special, and is why I keep coming back for more.
XDA Developers was founded by developers, for developers. It is now a valuable resource for people who want to make the most of their mobile devices, from customizing the look and feel to adding new functionality.
All yields aren't equal, and that is the case with the Net Payout Yield. Altria Group (NYSE:MO) doesn't offer investors the highest yield, but the tobacco company has one of the better yields on the market now. My investment thesis is Bullish on the stock, with the strong NPY signal topping 10% as the buyback repurchases cheap shares.
Covered entities should always ensure they are adhering to all federal, state, and local laws. Covered entities contracting with pharmacies to dispense 340B drugs should be aware of the federal anti-kickback statute and the way in which such requirements could apply to their arrangements with contract pharmacies. Cases of suspected violations of the anti-kickback statute should be directly referred to the Office of the Inspector General (OIG) who oversees this provision. The OIG can be reached at:
Hospitals become ineligible for the 340B Program on the day a Medicare Cost Report (MCR) is filed with Centers for Medicare & Medicaid Services (CMS) with a DSH percentage below the applicable eligibility threshold. Hospital offsite outpatient facilities failing to the meet the registration eligibility requirements (listed as reimbursable on the MCR with associated outpatient costs and charges) become ineligible on the day the hospital files the MCR. If either occurs, the hospital should stop purchasing 340B drugs immediately and terminate their record in 340B OPAIS. If the hospital purchased while they were ineligible, the hospital should send the Office of Pharmacy Affairs (OPA) a self-disclosure to 340bselfdisclosure@hrsa.gov. HRSA may accept an amended MCR as long as it is considered the latest filed MCR by CMS. The hospital must submit a signed, dated, and electronically-stamped Worksheet S, along with other requested worksheets, as evidence the MCR was amended and filed with CMS. If the hospital chooses to file an amended MCR, the hospital may resume purchasing 340B covered outpatient drugs after the amended MCR is filed with CMS, sent to HRSA, and subsequently accepted by HRSA. The amended MCR may not be applied retroactively for 340B purposes and HRSA reserves the right to request additional documentation if necessary. The hospital may be liable for any 340B purchases made during the period of ineligibility between when the original MCR was filed to when the amended MCR was filed, depending on the specific circumstances of the case.
340B OPAIS has public search and reports functionalities, with limited public viewing privileges, that will still be available. Covered entity, manufacturer, and contract pharmacy profiles are still accessible for public viewing. All registration, recertification, change and termination requests for covered entities and manufacturers can perform these actions in 340B OPAIS and are only accessible by their respective AO and PC.
Authorized covered entities and manufacturers are only granted one AO and one PC per 340B record. A 340B record is defined as an individual manufacturer labeler code or covered entity 340B ID. For covered entity hospitals and their outpatient facilities, as well as community health centers and their associated grant sites, each record has one AO and one PC per record. There is a requirement for hospital covered entity types that the AO be the same for all child sites, but the PC may be a separate person for each record. For example, hospital A with three outpatient facilities has the same AO for all records, but may select a separate PC for each record. While each record has only one AO and PC, the PC is not required to be the same person on each record. Manufacturers with multiple labeler codes may select different AOs and PCs for each labeler code.
Manufacturers may log into the 340B OPAIS Pricing application and upload a formatted text/instrument file or manually enter the required data points containing their quarterly data. Specifics on the text/instrument file upload format can be found in the manufacturer user guide.
A hospital system owns and controls many hospitals, some of which are 340B participating hospitals. The 340B participating hospitals each have their own 340B Program identification number. The hospital system would like to negotiate prices for drugs used at their hospitals, including those that participate in the 340B Program. Does the above scenario violate the 340B GPO prohibition? That is, does it constitute a group purchasing arrangement?
Yes. All covered entities may participate in the PVP, although disproportionate share hospitals, children's hospitals, and freestanding cancer centers that participate in the 340B Program are prohibited from purchasing covered outpatient drugs through a GPO. 340B Prime Vendor participation is voluntary, and there are no restrictions placed on covered entities electing to participate. Most alternative purchasing groups serving 330 grantees and other entities encourage participation in the 340B PVP to ensure members have access to best pricing on pharmaceuticals while offering members their own contract portfolios of medical/surgical, dental, office, and other non-pharmacy supplies, which tend to be complementary to the 340B PVP pharmacy portfolio. On occasion, there may be an alternative purchasing group that does not permit a member to simultaneously access their own contracts and 340B PVP contracts due to existing business relationships with a supply partner. In this situation, the covered entity may be required to notify the alternative purchasing group to cancel its membership before the selected pharmacy wholesaler will load the 340B PVP pricing available to the entity's pharmacy account.
Covered entities may only distribute 340B drugs to their employees that meet section 340B(a)(5)(B) of the Public Health Service Act. the patient definition guidelines set forth under the 340B Program. For more information, current patient definition guidelines, see 61 Fed. Reg. 55156 (Oct. 24, 1996). The 340B Program is limited to patients of the covered entity and has never been a general employee pharmacy benefit or self-insured organization pharmacy benefit. Evidence of an employer relationship or insurer relationship alone is insufficient to determine 340B patient eligibility.
No. Covered entities are free to choose how they will provide 340B pharmacy services to their patients, subject to federal and state laws. Options include contracting with a retail pharmacy, providing in-house pharmacy services, administering drugs to patients, etc. For more information, including tools and technical assistance in providing 340B pharmacy services, contact Apexus Answers at 888-340-2787, or ApexusAnswers@340bpvp.com.
HRSA audits of covered entities include contract pharmacy arrangements. The covered entity must have fully auditable records that demonstrate compliance with all 340B Program requirements and the entity remains responsible for ensuring their contract pharmacy arrangements meet statutory obligations to ensure against diversion or duplicate discounts. HRSA recommends that covered entities perform quarterly internal audits and annual independent audits (or more frequent as necessary) of all their utilized contract pharmacies to ensure 340B Program compliance. HRSA also recommends that covered entities maintain written policies and procedures to describe contract pharmacy oversight activities, including effective procedures for review of the patient eligibility determination system used at contract pharmacies, and reconciliation of dispensing, purchasing, and billing records to ensure that diversion and duplicate discounts have not occurred. 2ff7e9595c
Comments